Special ArticleRecommendations by the Spanish Society of Rheumatology on OsteoporosisRecomendaciones de la Sociedad Española de Reumatología sobre osteoporosis☆
Section snippets
Introduction and objectives
Osteoporosis (OP) is a diffuse skeletal disorder characterised by a general reduction in bone strength leading to a higher risk of fracture due to fragility.
In Spain and in other countries the rate of fragility fractures is increasing, mainly due to higher life expectancies.1 One study reported that in 2010 2.4 million Spaniards (1.9 million women and 0.5 men) over 50 suffered from OP,2 and as a consequences of this there were 204,000 new fractures at a cost of 2842 million euros (2.8%of the
Design
Qualitative synthesis of scientific evidence and consensus techniques have been used in this project which reflect the agreement by experts based on their clinical experience and scientific evidence.
Procedural stages
A series of steps were taken during the development of the recommendations document, which were:
- 1.
Creation of the work group. The document began with the formation of a panel of experts formed by 9 SER member rheumatologists. They were selected through an open call to all SER members. The Clinical
Results
There is a total of 28 formulated recommendations on OP (Table 1).
Definition and diagnosis
OP is a diffuse skeletal disease characterised by a reduction in bone resistance which leads to a higher risk of fragility fractures. The concept of “bone resistance” encompasses factors relating both to bone mineral density (BMD) and the quality of the bone tissue.6
A fragility fracture is that brought on by a low impact trauma. A fall, standing up or being seated would be included in this concept. The most frequent and relevant fractures are those of the proximal femur, the spine and the
Non pharmacological therapies
Recommendation: Included in the prevention of primary and secondary osteoporosis and fractures is the recommendation for a healthy lifestyle, consisting of a balanced diet and regular physical exercise, not smoking, limiting alcohol consumption and using preventative measures against falls (RR: √; AL: 100%).
Several studies have concluded that the first step to the prevention of OP and the avoidance of fractures is to maintain healthy life habits.53, 54, 55, 56, 57 Evidence suggests that
Fragility fracture
Recommendation: It is recommended that all patients’ ≥50 years of age with a recent fragility fracture be assessed systematically to prevent further fractures (RR: D; AL: 100%).
Patients with fragility fracture have a significant increase in the risk of further fractures. However, it is normal that fewer than 25% of them start treatment for OP after a fracture.4 The term “imminent fracture risk” has recently been introduced to refer to patients with recent fractures, fragile elderly people with
New treatments
Two new drugs for OP treatment: romosozumab and abaloparatide are currently in an advanced phase of clinical development.
Romosozumab is a humanised IgG2 monoclonal antibody which links and blocks sclerostin. It is administered monthly subcutaneously for a year, followed by denosumab or alendronic acid for a further year and has shown a significant reduction in the incidence of new vertebral and non vertebral fractures.225, 226 in one of the studies an increase in the rate of serious adverse
Conclusion
As mentioned in the introduction, the aim of this document was to provide an update on the new advances in the different aspects of OP relating to clinical practice: diagnosis, evaluation, treatment and follow-up.
The document is based on a critical review of the previous consenus,5 the best available scientific evidence and expert clinical experience. This was a joint task between panel members and the SER Unit of Research which, together with SER reviewers, carried out an extensive systematic
Conflict of interests
Antonio Naranjo Hernández received financing from Amgen, Lilly and FAES for attendance to courses/congresses, fees from Amgen for congress presentations and grants from FHOEMO-Amgen and Lilly to contract staff and provide IT teams to the service.
María Pilar Aguado Acín received financing from Lilly for attendance to congresses; fees from Alexion, Faes, Lilly and de Rubió for presentations and financing for educational programmes in the Rheumatology Unit.
Luis Arboleya Rodríguez received
Acknowledgements
The group of experts of this study wish to express their gratitude to Mercedes Guerra Rodríguez, the SER documentalist for her collaboration in search strategies and to Dr. Hye Sang Park for her collaboration in the RS report reviews. They also wish to thank Dr. Federico Diaz González, director of the SER Research Unit, for his participation in the final manuscript review and for contributing to maintaining the independence of this document.
References (227)
- et al.
2011 Up-date of the consensus statement of the Spanish Society of Rheumatology on osteoporosis
Reumatol Clin
(2011) - et al.
Probability of fractures predicted by FRAX® and observed incidence in the Spanish ECOSAP Study cohort
Bone
(2012) - et al.
Umbrales de FRAX para determinar personas con alto y bajo riesgo de fractura osteoporótica en población femenina española
Med Clin (Barc)
(2015) - et al.
Fracture experience among participants from the FROCAT study: what thresholding is appropriate using the FRAX tool?
Maturitas
(2016) - et al.
Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on Bone Densitometry
J Clin Densitom
(2013) - et al.
Assessment of a set of FRAX®-based criteria for the indication of bone densitometry in Spanish postmenopausal women
Med Clin (Barc)
(2013) - et al.
[FRAX® thresholds to identify people with high or low risk of osteoporotic fracture in Spanish female population]
Med Clin (Barc)
(2015) - et al.
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG
J Bone Oncol
(2017) - et al.
Trabecular bone score: a new DXA-derived measurement for fracture risk assessment
Endocrinol Metab Clin North Am
(2017) - et al.
Trabecular bone score (TBS): method and applications
Bone
(2017)
American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2016
Endocr Pract
Clinical practice guidelines for posmenopausal, glucocorticoid-induced and male osteoporosis. Spanish Society for Research on Bone and Mineral Metabolism (3rd updated version 2014)
Rev Clin Esp
Opportunistic identification of vertebral fractures
J Clin Densitom
Height loss, vertebral fractures, and the misclassification of osteoporosis
Bone
Urinary tract stone occurrence in the Women's Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements
Am J Clin Nutr
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group
Lancet
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
Lancet
Changing trends in the epidemiology of hip fracture in Spain
Osteoporos Int
Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)
Arch Osteoporos
SCOPE: a scorecard for osteoporosis in Europe
Arch Osteoporos
The osteoporosis treatment gap
J Bone Miner Res
Osteoporosis prevention, diagnosis, and therapy
JAMA
The burden of osteoporotic fractures: a method for setting intervention thresholds
Osteoporos Int
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group
World Health Organ Tech Rep Ser
Assessment of osteoporosis at the primary health-care level. Technical report
The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group
Osteoporos Int
Clinical practice. Postmenopausal osteoporosis
N Engl J Med
Imminent fracture risk
Osteoporos Int
Imminent risk of fracture after fracture
Osteoporos Int
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women
Osteoporos Int
Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group
N Engl J Med
Risk assessment tools to identify women with increased risk of osteoporotic fracture: complexity or simplicity? A systematic review
J Bone Miner Res
The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis
Ann Rheum Dis
Interpretation and use of FRAX in clinical practice
Osteoporos Int
Validación del modelo predictivo de fractura osteoporótica FRAX. Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad, Política Social e Igualdad
FRAX® tool, the WHO algorithm to predict osteoporotic fractures: the first analysis of its discriminative and predictive ability in the Spanish FRIDEX cohort
BMC Musculoskelet Disord
Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
BMJ
Hip fracture in women without osteoporosis
J Clin Endocrinol Metab
Low-trauma fractures without osteoporosis
Osteoporos Int
Clinical use of bone densitometry: scientific review
JAMA
Official positions of the international society for clinical densitometry
J Clin Endocrinol Metab
Clinician's guide to prevention and treatment of osteoporosis
Osteoporos Int
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary
CMAJ
Predictive value of a multi-biomarker disease activity score for successful dose reduction of TNF inhibitors in rheumatoid arthritis: results of the dress study
Ann Rheum Dis
2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis
Arthritis Rheumatol
The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation
Oncotarget
Is bone microarchitecture status of the lumbar spine assessed by TBS related to femoral neck fracture? A Spanish case-control study
Osteoporos Int
Adjusting fracture probability by trabecular bone score
Calcif Tissue Int
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
Osteoporos Int
Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents
J Clin Endocrinol Metab
Cited by (0)
- ☆
Please cite this article as: Naranjo Hernández A, Díaz del Campo Fontecha P, Aguado Acín MP, Arboleya Rodríguez L, Casado Burgos E, Castañeda S, et al. Recomendaciones de la Sociedad Española de Reumatología sobre osteoporosis. Reumatol Clin. 2019;15:188–210.